Prostate cancer is one of the country’s largest public health problems in men. As such, we have seen rapid increase in the use of MRI for the diagnosis and management of prostate cancer. High financial and resource burdens have given rise to concerns about the quality of prostate MRI scans and interpretation, lack of consensus among stakeholders, variability in insurance coverage and an apparent disconnect between supportive data and payer guidelines and policies.
For these reasons, the ACR convened a multistakeholder MR Prostate Summit at ACR headquarters in Reston, Virginia, on Sept. 6, 2019. Representatives from various professional medical organizations joined the ACR for the summit, including:
- American Urological Association
- American Society of Clinical Oncology
- American Society for Radiation Oncology
- Society of Nuclear Medicine and Molecular Imaging
The goals of the MR Prostate Summit were to:
- Share current data about prostate MRI and other tests (including nuclear medicine) in biopsy-naïve men and those patients managed on active surveillance/watchful waiting
- Illuminate strengths and limitations of the data
- Propose strategies to build common ground across specialties and stakeholders about the role of MRI in prostate cancer diagnosis and management
- Identify obstacles and make recommendations to the ACR, other professional organizations and insurers
Results and recommendations will be published soon.